La Jolla Pharmaceutical Co

La Jolla Pharmaceutical — Investor Presentation (July 2014)

37 slides from La Jolla Pharmaceutical's investor presentation, Jul 22, 2014

  1. Slide 1: Corporate Presentation

    Corporate Presentation NasdaqCM: LJPC July 2014 Developing Innovative Therapies for Patients Suffering from Life-threatening Diseases

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "anticipate", "believe", "continue", "could", "estimate", "exp

  3. Slide 3: Overview of LJPC

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH GCS-100 (IV Galectin-3 Inhibitor) for CKD LJPC-1010 (Oral Galectin-3 Inhibitor) for NASH LJPC-401 (Hepcidin) for Iron Overload Financial Position and Milestones

  4. Slide 4: Product Pipeline

    Product Pipeline GCS-100 IV Galectin-3 Inhibitor LJPC-1010 Oral Galectin-3 Inhibitor LJPC-501 Angiotensin II LJPC-401 Hepcidin Other R&D Preclinical IND Phase 1 Phase 2 Phase 3 CKD NASH Underway Completed ESRD Planned H2 2016 H1 2016 HRS CRH H1 2016 4 Early 2015 H2 2016 2b Early 2015 2015 Iron Overl

  5. Slide 5: Overview of LJPC

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH GCS-100 (IV Galectin-3 Inhibitor) for CKD LJPC-1010 (Oral Galectin-3 Inhibitor) for NASH LJPC-401 (Hepcidin) for Iron Overload Financial Position and Milestones

  6. Slide 6: LJPC-501 for CRH: Overview

    LJPC-501 for CRH: Overview • LJPC-501 is a proprietary formulation of angiotensin II, a naturally occurring regulator of blood pressure • Catecholamine-resistant hypotension (CRH) is an acute, life- threatening condition in which blood pressure drops to dangerously low levels and is unresponsive to

  7. Slide 7: What Is CRH?

    What Is CRH? Hypotension = low blood pressure that is below the normal perfusion blood pressure (MAP < 60-65 mmHg) • Treated with fluids and catecholamines  Epinephrine (adrenaline)  Norepinephrine (noradrenaline)  Dopamine • Some patients require excessive doses and are found to be resistant 7 A

  8. Slide 8: Even Short Periods of Hypotension Are Associated with Serious Adverse Events

    Even Short Periods of Hypotension Are Associated with Serious Adverse Events 8 Reference: Anesthesiology 2013, 119;3, 507-515. Predicted probability of (A) acute kidney injury and (B) myocardial injury by lowest mean arterial pressure (MAP) experienced during surgery

  9. Slide 9: What Is LJPC-501?

    What Is LJPC-501? • Proprietary, stable formulation of synthetic angiotensin II • Endogenous eight-amino acid peptide that is central to the renin-angiotensin system  Known to raise blood pressure (BP)  Angiotensin-converting enzyme (ACE) inhibitors lower BP by inhibiting synthesis of angiotensin

  10. Slide 10: Angiotensin II Raises Blood Pressure in Hypotensive Pig Model

    Angiotensin II Raises Blood Pressure in Hypotensive Pig Model 10 Reference: Correa,TD, et al. 2014 Crit Care Med. Epubication ahead of print 0 20 40 60 80 100 BL EOP RP 12h RP 24h RP 36h RP 48h M A P ( m m H g ) Time NE E AT-IInorepinephrine enalapril + norepinephrine angiotensin II

  11. Slide 11: Angiotensin II Raises Blood Pressure in CRH Pilot Trial

    Angiotensin II Raises Blood Pressure in CRH Pilot Trial 11 Reference: Busse, LW, et al. 2014, Critical Care 18(Suppl 1), 160 • Randomized, placebo-controlled, double-blind pilot trial • 20 patients; 10 per arm • Primary efficacy endpoint  Catecholamine dose sparing; surrogate for BP effect • Safety

  12. Slide 12: Norepinephrine Dose Decreases with Angiotensin II

    Norepinephrine Dose Decreases with Angiotensin II Surrogate Effect on Blood Pressure 12 0 5 10 15 20 25 30 35 40 45 50 Pre2 Pre1 Hr0 Hr1 Hr2 Hr3 Hr4 Hr5 Hr6 Post1 Post2 N ore p in e p h ri n e D o s e (mcg/ m in ) Placebo AT-II Arm Angio dose % of Patients with Rise in BP: Placebo Group 20% vs. Angi

  13. Slide 13: High Dose Norepinephrine Is Associated with Very Poor Outcome

    High Dose Norepinephrine Is Associated with Very Poor Outcome 13 References: Sviri, S., et al. 2014 J. of Crit Care 29, 157-160. JAMA 2013 Oct23/30 310:1683-1691 • Catecholamines cause cardiac toxicity, digital necrosis and metabolic complications leading to higher mortality 0 10 20 30 40 50 60 70 8

  14. Slide 14: Planned Phase 3 Trial of LJPC-501 in CRH

    Planned Phase 3 Trial of LJPC-501 in CRH 14 • Randomized, placebo-controlled, blinded Phase 3 trial • Patient population: catecholamine-resistant, based on CV SOFA* score • Primary endpoint: blood pressure • Primary endpoint duration: short-term to primary endpoint (hours) • Size: 200-300 patients,

  15. Slide 15: Summary of LJPC-501 in CRH

    Summary of LJPC-501 in CRH 15 • LJPC-501 is a proprietary formulation of angiotensin II, a naturally occurring regulator of blood pressure • Catecholamine-resistant hypotension (CRH) is an acute, life- threatening condition in which blood pressure drops to dangerously low levels and is unresponsive

  16. Slide 16: Overview of LJPC

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH GCS-100 (IV Galectin-3 Inhibitor) for CKD LJPC-1010 (Oral Galectin-3 Inhibitor) for NASH LJPC-401 (Hepcidin) for Iron Overload Financial Position and Milestones

  17. Slide 17: Galectins and Galectin-3

    Galectins and Galectin-3 17 • Galectin-3 is unique because it has the ability to self-associate (multimerize) up to a pentameric form, allowing it to bind to several receptors at once • Galectin-3 is normally present at low concentration, but is up-regulated in organ failure and cancer; increased le

  18. Slide 18: Galectin-3 and Organ Failure

    Galectin-3 and Organ Failure Epidemiology and Causative Link Clinical Epidemiology • Higher galectin-3 levels in normal individuals are associated with reduced survival1 • Galectin-3 predicts CKD risk in the general population2 • Galectin-3 serum assay is FDA approved to identify patients at risk fo

  19. Slide 19: GCS-100: The Leading Galectin-3 Antagonist Mechanism of Action

    GCS-100: The Leading Galectin-3 Antagonist Mechanism of Action 19 • GCS-100 is a well-characterized, complex sugar derived from pectin • GCS-100 binds to and neutralizes galectin-3; binding activity is localized to the galactose containing side-branches • Patented manufacturing process required for

  20. Slide 20: Phase 1 Data Validates Galectin-3 as a Target in CKD

    Phase 1 Data Validates Galectin-3 as a Target in CKD r²=0.36191 p=0.003 0 10 20 30 40 50 60 70 80 0 10 20 30 40 50 60 G a l- 3 ng /m L eGFR (mL/min/1.73m2) 20 • Single-dose, Phase 1 dose escalation trial complete • 30 mg/m2 MTD • 1/6 patients at 30 mg/m2 experienced reversible, self-limited muscle c

  21. Slide 21: Phase 2a CKD Trial Design

    Phase 2a CKD Trial Design 21 Day 1 Day 57 Dosing, IV PBO or GCS-100 at 1.5 or 30 mg/m2 D -1 D -8 D -2 2 D -2 9 D -3 6 D -4 3 D -5 0 1o Endpoint: eGFR change vs. placebo 2o Endpoint: safety and tolerability Exploratory Endpoints: circulating galectin-3, markers of inflammation, fibrosis and renal inj

  22. Slide 22: Evaluation of Phase 2a Doses Based on PK/PD

    22 Evaluation of Phase 2a Doses 30 mg/m2 Is Too High Based on PK/PD 0 200 400 600 800 1000 1200 1400 1600 0 50 100 150 200 M o le s G C S -1 0 0/ M o le G a l- 3 Hours post-infusion GCS-100/Gal-3 Ratio 30 mg/m2 Pharmacologic overdose may lead to adverse off-target effects 0 5 10 15 20 25 30 35 40 45

  23. Slide 23: Time Course of Activity Consistent with MoA

    -2.5 -2 -1.5 -1 -0.5 0 0.5 0.0 1.0 2.0 3.0 Published CKD Natural Hx Phase 2 Study Placebo Patients Time Course of Activity Consistent with MoA Placebo Group Consistent with Natural Hx of CKD 23 Efficacy Endpoint Also Met at End of Study Time Point (5 Weeks post Last Dose) Placebo Data Consistent wit

  24. Slide 24: Safety Data Summary

    Early Terminations • 117 of 121 patients enrolled completed the study  Placebo: 40/41 completed; 1 withdrew consent after the first dose  1.5 mg/m2: 41/41 completed  30 mg/m2: 36/39 completed; 1 withdrew consent before the first dose, 1 withdrew consent after the second dose due to scheduling con

  25. Slide 25: GCS-100 CKD Phase 2 Results

    • Primary endpoint reached for 1.5 mg/m2 dose • eGFR effect correlates with change in galectin-3 • Multiple secondary endpoints improved and consistent with primary endpoint analysis GCS-100 CKD Phase 2 Results 25 Placebo 1.5 mg/m2 Change P-value Change P-value Comparator eGFR -0.58 – 1.26 0.045 vs.

  26. Slide 26: Potential Phase 2b Study Design

    • OBJECTIVE Compare efficacy of 3 doses versus placebo • PRIMARY ENDPOINT Sustained improvement in eGFR versus placebo • SECONDARY ENDPOINTS Rate of CV events Potential Phase 2b Study Design 26 1 :1 :1 :1 R an d omi za ti o n • Stage: 3 and 4 • eGFR: high baseline variability excluded • Other: • Eti

  27. Slide 27: Overview of LJPC

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH GCS-100 (IV Galectin-3 Inhibitor) for CKD LJPC-1010 (Oral Galectin-3 Inhibitor) for NASH LJPC-401 (Hepcidin) for Iron Overload Financial Position and Milestones

  28. Slide 28: LJPC-1010: Overview

    LJPC-1010: Overview 28 • LJPC-1010 is a more potent and purified derivative of GCS- 100 that can be delivered orally • Nonalcoholic steatohepatitis (NASH) is the more serious form of nonalcoholic fatty liver disease (NAFLD), which can lead to liver failure; NASH affects 2 to 5 percent of Americans •

  29. Slide 29: LJPC-1010: Effect in NASH Model

    LJPC-1010: Effect in NASH Model 29 • In a preclinical study of liver fibrosis in the STAM model of NASH, comparing LJPC-1010 to placebo, LJPC-1010 showed a significant reduction (p<0.001) vs. control vehicle in NAFLD activity score • LJPC-1010 showed a significant impact on steatosis (fat accumulati

  30. Slide 30: LJPC-1010: Improves Histology

    LJPC-1010: Improves Histology Phase 1/2 Planned for Early 2015 30 Control Vehicle GCS-100 LJPC-1010 • Next Steps:  Bridging toxicology studies GMP manufacturing  Phase 1/2 early 2015

  31. Slide 31: Overview of LJPC

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH GCS-100 (IV Galectin-3 Inhibitor) for CKD LJPC-1010 (Oral Galectin-3 Inhibitor) for NASH LJPC-401 (Hepcidin) for Iron Overload Financial Position and Milestones

  32. Slide 32: LJPC-401: Overview

    LJPC-401: Overview • LJPC-401 is a formulation of hepcidin, which is an endogenous peptide hormone that controls and regulates iron metabolism • Several large indications  Acquired iron overload –Currently treated with chelators; 50% of patients are intolerant to or fail –Approximately 25,000 patie

  33. Slide 33: LJPC-401: Hepcidin

    LJPC-401: Hepcidin • Hepcidin: the insulin of iron metabolism Regulates iron absorption and disposition in all organs Rapid and sustained lowering of blood iron levels • Next Steps  Evaluating SQ formulation  Phase 1 early 2015 33 single 50ug IP injection into a mouse

  34. Slide 34: Overview of LJPC

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH GCS-100 (IV Galectin-3 Inhibitor) for CKD LJPC-1010 (Oral Galectin-3 Inhibitor) for NASH LJPC-401 (Hepcidin) for Iron Overload Financial Position and Milestones

  35. Slide 35: Condensed Statement of Cash Flow Data / Financial Position

    Condensed Statement of Cash Flow Data Twelve Months Ended March 31, 2014 (in millions) Cash used for operating activities $6.8 Financial Position 35 Condensed Balance Sheet Data As of March 31, 2014 (in millions) Cash $5.9 Total liabilities $0.9 Total stockholders’ equity $5.2 Fully Diluted, As-Conv

  36. Slide 36: Development Plan

    Development Plan 36 2017 2015 2016 2014 Today Phase 2b G C S -1 0 0 Phase 1 Phase 2a extension Phase 3 L J P C -5 0 1 Phase 2/3 Phase 3 Phase 1/2 CRH HRS CKD ESRD IND H2 2014 H2 2015 [DATE] H1 2016 H1 2015 Late 2014 H2 2016 H2 2016 Not Budgeted L J P C -4 0 1 Iron O v er lo a d Phase 1 Preclinical /

  37. Slide 37: Thank You

    / @Lavolla Thank You

LA Jolla Pharmaceutical — Investor Presentation (July 2014) on 6ix